Αρχική World News FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and... World News FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Από Ogkologos - 18 Ιουλίου, 2025 875 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Addressing Cancer Pain with Complementary Methods (Part 1) 7 Απριλίου, 2023 The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... 16 Ιουλίου, 2018 FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe... 20 Νοεμβρίου, 2019 KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,... 3 Αυγούστου, 2022 Φόρτωση περισσοτέρων HOT NEWS Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC Workout Wednesdays – Leg Exercises Part 3 EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab) How could proposed changes to data protection laws affect research?